Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC

McDonagh, Theresa A.; Metra, Marco; Adamo, Marianna; Gardner, Roy S.; Baumbach, Andreas; Böhm, Michael; Burri, Haran; Butler, Javed; Čelutkienė, Jelena; Chioncel, Ovidiu; Cleland, John G.F.; Coats, Andrew J.S.; Crespo‐Leiro, María G.; Farmakis, Dimitrios; Gilard, Martine; Heymans, Stéphane; Hoes, Arno W.; Jaarsma, Tiny; Jankowska, Ewa A.; Lainščak, Mitja; Lam, Carolyn S.P.; Lyon, Alexander R.; McMurray, John J.V.; Mebazaa, Alexandre; Mindham, Richard; Muneretto, Claudio; Piepoli, Massimo F; Price, Susanna; Rosano, Giuseppe; Ruschitzka, Frank; Skibelund, Anne Kathrine

doi:10.1093/eurheartj/ehab670

Cited by 1,394 publications

(3,154 citation statements)

References 0 publications

Supporting

Mentioning

2,995

Contrasting

Unclassified

115

Order By: Relevance

“…The inclusion criteria of the HFpEF group required compliance with the HFpEF diagnostic criteria in the “2021 ESC Guidelines for the Heart Failure” ( 20 ). The inclusion criteria of the control group included people with no cardiovascular diseases such as high blood pressure, coronary heart disease, cardiomyopathy, pericardial disease, and valvular heart disease.…”

Section: Methodsmentioning

confidence: 99%

Gut Microbiota in Heart Failure Patients With Preserved Ejection Fraction (GUMPTION Study)

Huang,

Mei,

Jiang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Introduction: Heart failure with preserved ejection fraction (HFpEF) is associated with disrupted intestinal epithelial function, resulting from intestinal congestion. Intestinal congestion changes the morphology and permeability of the intestinal wall, and it becomes easy for the gut microbiota to change and transfer. Intervention on gut microbiota may become a new target for HFpEF treatment. However, the characteristics of gut microbiota in patients with HFpEF remain unknown. This preliminary report aims to detect the structure of gut microbiota in HFpEF patients so as to explore their characteristic changes, thereby providing a theoretical basis for future research.Methods: This research recruited 30 patients diagnosed with HFpEF and 30 healthy individuals. Stool specimens of research subjects were collected separately, and the microarray analyses of gut microbiota were conducted by Illumina high-throughput DNA sequencing. The differences in gut microbiota composition, alpha diversity, and beta diversity between the two groups were finally obtained.Results: The composition of gut microbiota was significantly different between the two groups. At the phylum classification level, the abundance of Synergistetes tended to be higher in the HFpEF group (P = 0.012). At genus classification level, the abundance of Butyricicoccus (P < 0.001), Sutterella (P = 0.004), Lachnospira (P = 0.003), and Ruminiclostridium (P = 0.009) in the HFpEF group were lower, while the abundance of Enterococcus (P < 0.001) and Lactobacillus (P = 0.005) were higher. According to the Chao index of alpha diversity analysis, HFpEF patients showed a nominally significant lower species richness when compared with controls (P = 0.046). However, there was no statistical difference in the Shannon index (P = 0.159) and Simpson index (P = 0.495), indicating that there was no difference in species diversity between the two groups. Beta diversity analysis revealed a highly significant separation of HFpEF patients and controls.Conclusions: An imbalance in the gut microbiota of HFpEF patients was observed. Patients with HFpEF have an increased abundance of microbiota associated with inflammation and a decreased abundance of microbiota associated with anti-inflammatory effects in the gut environment. In line with that, the species richness of gut microbiota in HFpEF patients tended to be lower.

show abstract

Section: Methodsmentioning

confidence: 99%

Gut Microbiota in Heart Failure Patients With Preserved Ejection Fraction (GUMPTION Study)

Huang,

Mei,

Jiang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Within a decade since the first clinical trial in diabetes, SGLT2 inhibitors are now recommended as the first-line therapy for patients with HF with reduced ejection fraction (HFrEF). 6 Furthermore, SGLT2 inhibitors have been shown to reduce HF hospitalization and mortality in patients with HF with preserved ejection fraction (HFpEF). 41 …”

Section: Cardiovascular Effects Of Sglt2 Inhibitorsmentioning

confidence: 99%

“… 1 2 3 4 5 In the past decades, advances in medical and device-based therapy have considerably improved outcomes for HF patients. 6 Nevertheless, the mortality rates continue to be very high. 7 For instance, a recent meta-analysis demonstrated that the 10-year survival rate of HF is only 34.9%, irrespective of the cause of HF.…”

Section: Introductionmentioning

confidence: 99%

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure

Saucedo-Orozco

Voorrips

Yurista

et al. 2022

J Lipid Atheroscler

View full text Add to dashboard Cite

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as powerful drugs that can be used to treat heart failure (HF) patients, both with preserved and reduced ejection fraction and in the presence or absence of type 2 diabetes. While the mechanisms underlying the salutary effects of SGLT2 inhibitors have not been fully elucidated, there is clear evidence for a beneficial metabolic effect of these drugs. In this review, we discuss the effects of SGLT2 inhibitors on cardiac energy provision secondary to ketone bodies, pathological ventricular remodeling, and inflammation in patients with HF. While the specific contribution of ketone bodies to the pleiotropic cardiovascular benefits of SGLT2 inhibitors requires further clarification, ketone bodies themselves may also be used as a therapy for HF.

show abstract

“…In order to avoid misdiagnosis of myocarditis in patients with COVID-19, we recommend implementing the structured diagnostic algorithm, included in the guidelines created by European Society of Cardiology [ 24 , 25 ]. It should be highlighted that nasal/throat swab tests for COVID-19 in the presence of clinically suspected myocarditis does not allow for establishing the etiology.…”

Section: Discussionmentioning

confidence: 99%

Sex Differences in Incidence, Clinical Characteristics and Outcomes in Children and Young Adults Hospitalized for Clinically Suspected Myocarditis in the Last Ten Years—Data from the MYO-PL Nationwide Database

Ozierański

Tymińska

Skwarek

et al. 2021

JCM

View full text Add to dashboard Cite

There is a widespread lack of systematic knowledge about myocarditis in children and young adults in European populations. The MYO-PL nationwide study aimed to evaluate sex differences in the incidence, clinical characteristics, management and outcomes of all young patients with a clinical diagnosis of myocarditis, hospitalized in the last ten years. The study involved data (from the only public healthcare insurer in Poland) of all (n = 3659) patients aged 0–20 years hospitalized for myocarditis in the years 2011–2019. We assessed clinical characteristics, management and five-year outcomes. Males comprised 75.4% of the study population. The standardized incidence rate of myocarditis increased over the last ten years and was, on average, 7.8 and 2.5 (in males and females, respectively). It was the highest (19.5) in males aged 16–20 years. The highest rates of hospital admissions occurred from late autumn to early spring. Most myocarditis-directed diagnostic procedures, including laboratory tests, echocardiography, coronary angiography, cardiac magnetic resonance and endomyocardial biopsy, were performed in a low number of patients, particularly in females. Most patients required rehospitalization for cardiovascular reasons. The results of this large epidemiological study showed an increasing incidence of myocarditis hospitalizations in young patients over last ten years and that it was sex-, age- and season-dependent. Survival in young patients with myocarditis was age- and sex-related and usually it was worse than in the national population. The general management of myocarditis requires significant improvement.

show abstract

Cited by 1,394 publications

References 0 publications

Gut Microbiota in Heart Failure Patients With Preserved Ejection Fraction (GUMPTION Study)

Gut Microbiota in Heart Failure Patients With Preserved Ejection Fraction (GUMPTION Study)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure

Sex Differences in Incidence, Clinical Characteristics and Outcomes in Children and Young Adults Hospitalized for Clinically Suspected Myocarditis in the Last Ten Years—Data from the MYO-PL Nationwide Database

Contact Info

Product

Resources

About